{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:16:49Z","timestamp":1790227009173,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jhep.2019.11.011","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T19:40:18Z","timestamp":1574883618000},"page":"670-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["B cell immunodominance in primary hepatitis C virus infection"],"prefix":"10.1016","volume":"72","author":[{"given":"Nicholas A.","family":"Brasher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auda A.","family":"Eltahla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Boo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-9880","authenticated-orcid":false,"given":"Melanie R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2189-9177","authenticated-orcid":false,"given":"Chaturaka","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi E.","family":"Drummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicodemus","family":"Tedla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena A.","family":"Bull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.11.011_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2019.11.011_bib2","doi-asserted-by":"crossref","first-page":"e1004297","DOI":"10.1371\/journal.ppat.1004297","article-title":"Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423","volume":"10","author":"Keck","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2019.11.011_bib3","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2019.11.011_bib4","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2019.11.011_bib6","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","author":"Hadlock","year":"2000","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib7","doi-asserted-by":"crossref","first-page":"e8254","DOI":"10.1371\/journal.pone.0008254","article-title":"Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes","volume":"4","author":"Mancini","year":"2009","journal-title":"PloS one"},{"key":"10.1016\/j.jhep.2019.11.011_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib9","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1128\/JVI.78.13.7257-7263.2004","article-title":"Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity","volume":"78","author":"Keck","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib10","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.11.011_bib11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.27298","article-title":"Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a","volume":"60","author":"Carlsen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.011_bib12","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33","volume":"88","author":"Tarr","year":"2007","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.28989","article-title":"The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs","volume":"65","author":"Vietheer","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.011_bib14","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.011_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jir835","article-title":"Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion","volume":"205","author":"Raghuraman","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2019.11.011_bib16","doi-asserted-by":"crossref","first-page":"e0165047","DOI":"10.1371\/journal.pone.0165047","article-title":"Hepatitis C virus broadly neutralizing monoclonal antibodies isolated 25 years after spontaneous clearance","volume":"11","author":"Merat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.11.011_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2019.11.011_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/jvh.12701","article-title":"Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study","volume":"24","author":"Cunningham","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.011_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5694\/mja13.00153","article-title":"Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study","volume":"201","author":"White","year":"2014","journal-title":"Med J Aust"},{"key":"10.1016\/j.jhep.2019.11.011_bib20","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1128\/JVI.02070-15","article-title":"Monoclonal antibodies directed toward the hepatitis C virus glycoprotein E2 detect antigenic differences modulated by the N-terminal hypervariable region 1 (HVR1), HVR2, and intergenotypic variable region","volume":"89","author":"Alhammad","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib21","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1128\/JVI.01332-10","article-title":"Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype","volume":"85","author":"Tarr","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib22","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1099\/jgv.0.000537","article-title":"Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay","volume":"97","author":"Urbanowicz","year":"2016","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction","volume":"22","author":"Rusert","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2019.11.011_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.28989","article-title":"The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs","volume":"65","author":"Vietheer","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.11.011_bib25","doi-asserted-by":"crossref","first-page":"e1002243","DOI":"10.1371\/journal.ppat.1002243","article-title":"Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection","volume":"7","author":"Bull","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2019.11.011_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12864-016-2575-8","article-title":"A\u00a0method for near full-length amplification and sequencing for six hepatitis C virus genotypes","volume":"17","author":"Bull","year":"2016","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jhep.2019.11.011_bib27","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1128\/JVI.03717-14","article-title":"Transmitted\/founder viruses rapidly escape from CD8+ T cell responses in acute hepatitis C virus infection","volume":"89","author":"Bull","year":"2015","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib28","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jvh.12615","article-title":"Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents","volume":"24","author":"Eltahla","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.11.011_bib30","doi-asserted-by":"crossref","first-page":"E6946","DOI":"10.1073\/pnas.1614942113","article-title":"Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: implications for vaccine design","volume":"113","author":"Pierce","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.11.011_bib31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3389\/fimmu.2018.00910","article-title":"Glycan shielding and modulation of hepatitis C virus neutralizing antibodies","volume":"9","author":"Lavie","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2019.11.011_bib32","first-page":"E82","article-title":"Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms","volume":"115","author":"Mankowski","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.11.011_bib33","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1172\/JCI130720","article-title":"Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance","volume":"130","author":"Kinchen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2019.11.011_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","article-title":"Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus","volume":"19","author":"Howell","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2019.11.011_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2144","article-title":"Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller","volume":"9","author":"Freund","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2019.11.011_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imr.12512","article-title":"Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem","volume":"275","author":"Havenar-Daughton","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhep.2019.11.011_bib37","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.0902749106","article-title":"Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.11.011_bib38","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.11.011_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ni.3684","article-title":"Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins","volume":"18","author":"Nachbagauer","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2019.11.011_bib40","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1073\/pnas.1822002116","article-title":"Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations","volume":"116","author":"Prentoe","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.11.011_bib41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41586-018-0517-0","article-title":"Tracing HIV-1 strains that imprint broadly neutralizing antibody responses","volume":"561","author":"Kouyos","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2019.11.011_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ni.3680","article-title":"Defining B cell immunodominance to viruses","volume":"18","author":"Angeletti","year":"2017","journal-title":"Nat Immunol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819306981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:37:15Z","timestamp":1759174635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819306981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0168827819306981"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.11.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell immunodominance in primary hepatitis C virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}